Acquisition Announced
UCB acquisition of Neurona Therapeutics
US$650m consideration
Announced 17 Apr 2026
Advisers
Neurona Therapeutics
Target
- Financial adviser
- Legal adviser
- Target
- Neurona Therapeutics
- Acquirer
- UCB
- Target based in
- United States
- Buyer based in
- Belgium
- Sector
- Biotech
- Tags
- Biotech, Cell Therapy, Pharma
In the league tables
Similar deals
- AstraZeneca acquisition of AbelZeta's 50% share of China development and commercialisation rights to C-CAR031 Jan 2026 · US$630m · Biotech
- Teva Pharmaceuticals acquisition of Emalex Biosciences Apr 2026 · US$700m · Pharma
- Otsuka acquisition of Transcend Therapeutics Mar 2026 · US$700m · Biotech
- Zymeworks acquisition of Theravance Biopharma Jun 2026 · US$929m · Pharma
- Galera Therapeutics and Obsidian Therapeutics merger Apr 2026 · US$414m · Biotech


